MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cytosorbents Corp Company Profile (OTCMKTS:CTSO)

Consensus Ratings for Cytosorbents Corp (OTCMKTS:CTSO) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.00

Analysts' Ratings History for Cytosorbents Corp (OTCMKTS:CTSO)
Show:
DateFirmActionRatingPrice TargetActions
6/15/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/29/2015WBB SecuritiesUpgradeSpeculative Buy -> Buy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2015MLV & Co.Lower Price TargetBuy$28.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Cytosorbents Corp (OTCMKTS:CTSO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/9/2016Q116($0.10)($0.08)$1.73 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.08)($0.08)$1.58 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2015Q315($0.10)($0.11)$1.26 million$1.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.11)$0.05$1.69 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.13)($0.11)$724.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.01)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.01)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2014($0.01)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Cytosorbents Corp (OTCMKTS:CTSO)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Cytosorbents Corp (OTCMKTS:CTSO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cytosorbents Corp (OTCMKTS:CTSO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/7/2016Michael G BatorDirectorBuy3,000$4.88$14,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2015Vincent CapponiCOOSell4,000$7.50$30,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Al KrausDirectorSell6,774$6.22$42,134.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2015Al KrausDirectorSell10,000$6.39$63,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2015Al KrausDirectorSell10,000$6.44$64,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2015Al KrausDirectorSell10,000$6.64$66,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2015Al KrausDirectorSell10,000$6.39$63,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2015Al KrausDirectorSell10,000$6.28$62,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015Al KrausDirectorSell10,000$6.33$63,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2015Al KrausDirectorSell10,000$5.98$59,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Al KrausDirectorSell13,205$7.33$96,792.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Al KrausDirectorSell10,000$5.78$57,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015Al KrausDirectorSell10,000$6.30$63,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2015Al KrausDirectorSell10,000$6.32$63,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2014Al KrausDirectorSell100,000$0.24$24,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014James T GuntonDirectorSell1,240,762$0.24$297,782.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2014Al KrausDirectorSell41,500$0.23$9,545.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Al KrausDirectorSell8,500$0.23$1,955.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014James T GuntonDirectorSell30,450$0.24$7,308.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2014James T GuntonDirectorSell100,000$0.24$24,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Al KrausDirectorSell50,000$0.25$12,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Kathleen P BlochCFOBuy65,000$0.23$14,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2014James T GuntonDirectorSell214,387$0.24$51,452.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014James T GuntonDirectorSell1,360,000$0.24$326,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Al KrausDirectorSell100,000$0.25$25,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Al KrausDirectorSell100,000$0.27$27,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Al KrausDirectorSell100,000$0.28$28,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/4/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014Kathleen P BlochCFOBuy110,000$0.24$26,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2012Phillip P ChanCEOBuy190,000$0.13$24,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Cytosorbents Corp (OTCMKTS:CTSO)
DateHeadline
06/30/16 03:43 PMEquity Research and Technical Review on Cytosorbents Corporation (NASDAQ:CTSO) - Press Telegraph
06/30/16 09:46 AMCytosorbents Corporation (NASDAQ:CTSO) Sellers Covered 0.72% of Their Shorts - Engelwood Daily
06/29/16 08:29 PMCytosorbents Corporation (NASDAQ:CTSO) Company Rating and Target Watch - Telanagana Press
06/27/16 03:29 PMShare Update and Earnings Review for Cytosorbents Corporation (NASDAQ:CTSO) - Press Telegraph
06/25/16 07:20 AMCytosorbents Corporation (NASDAQ:CTSO) Earnings Glance and Target Price Review - Engelwood Daily
06/25/16 07:20 AMCovering the Bases on Cytosorbents Corporation (NASDAQ:CTSO): Where is the Stock Going? - Press Telegraph
06/22/16 08:00 AMCytoSorbents Awarded $150,000 Phase I STTR Contract for Universal Plasma Development - [PR Newswire] - MONMOUTH JUNCTION, N.J., June 22, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy specializing in blood purification, announced that it was awarded ...
06/20/16 01:17 PMETF’s with exposure to CytoSorbents Corp. : June 20, 2016 -
06/13/16 07:30 AMCytoSorbents and Palex Bring CytoSorb® to Spain and Portugal - [PR Newswire] - MONMOUTH JUNCTION, N.J., June 13, 2016 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has signed an exclusive distributorship agreement with Palex Medical SA, one of Spain's largest independent medical device distributors, to bring its CytoSorb® therapy to Spain and Portugal. This multi-year agreement includes all critical care applications in these two countries, and is subject to annual minimum purchases of CytoSorb® to maintain exclusivity.
06/10/16 05:03 AMCYTOSORBENTS CORP Files SEC form 8-K, Change in Directors or Principal Officers -
06/08/16 01:12 PMCYTOSORBENTS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/03/16 10:59 AMCytosorbents Corp (CTSO) Stock Rating Reaffirmed by Maxim Group - Let Me Know About This
06/03/16 09:30 AMCTSO: Fresenius Commences Sales, DSMB Recommends Continuation of REFRESH I -
06/02/16 09:29 PMShare Rating Focus on Cytosorbents Corporation (NASDAQ:CTSO) - HNN - Share Rating Focus on Cytosorbents Corporation (NASDAQ:CTSO)HNNThis stock research may entail following what professional equity analysts think about the company. Presently, Wall Street analysts have given a consensus stock rating of 1.2 on shares of Cytosorbents Corporation (NASDAQ:CTSO). Covering analysts will ...and more »
06/02/16 10:28 AMTarget Price and Stock Performance Rundown for Cytosorbents Corporation (NASDAQ:CTSO) - HNN - Target Price and Stock Performance Rundown for Cytosorbents Corporation (NASDAQ:CTSO)HNNDuring the latest trading session, Cytosorbents Corporation (NASDAQ:CTSO) shares traded +4.43%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been seen ...and more »
06/01/16 04:55 PM5.27.16 CytoSorbents: DSMB Recommends Continuation of REFRESH I Trial - [at noodls] - ef13270c-80d5-4f87-8254-6595e1fd631b.pdf Independent Data Safety Monitoring Board Recommends Continuation of CytoSorbents REFRESH I Trial MONMOUTH JUNCTION, NJ - May 27, 2016 - CytoSorbents Corporation ...
06/01/16 10:33 AMCytoSorbents Announces Fresenius Medical Care Initiates Sales of CytoSorb® in France, Poland and Scandinavia - PR Newswire (press release) - CytoSorbents Announces Fresenius Medical Care Initiates Sales of CytoSorb® in France, Poland and ScandinaviaPR Newswire (press release)MONMOUTH JUNCTION, N.J., June 1, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood purification cartridge to prevent or treat deadly inflammation and ...and more »
06/01/16 06:00 AMCytoSorbents Announces Fresenius Medical Care Initiates Sales of CytoSorb® in France, Poland and Scandinavia - [PR Newswire] - MONMOUTH JUNCTION, N.J., June 1, 2016 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood purification cartridge to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, announced that Fresenius Medical Care (FMC), its strategic partner for acute care indications in France, Poland, Sweden, Denmark, Finland, and Norway, has officially initiated its CytoSorb® sales efforts. As part of its acute care business, Fresenius Medical Care has deployed a commercial team of sales, marketing, and medical experts to drive sales of CytoSorb®. This team, which is highly experienced and actively sells Fresenius' products into intensive care units, has been trained and is leading CytoSorb® marketing and sales efforts throughout the territory.
05/30/16 07:16 AM8:16 am CytoSorbents indicated higher after Independent Data Safety Monitoring Board recommends continuation of CytoSorbents REFRESH I trial -
05/27/16 07:00 AMIndependent Data Safety Monitoring Board Recommends Continuation of CytoSorbents REFRESH I Trial - [PR Newswire] - MONMOUTH JUNCTION, N.J., May 27, 2016 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood purification cartridge to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, announced that the independent Data Safety Monitoring Board (DSMB) of the current U.S. REFRESH I cardiac surgery trial positively evaluated the safety data from the first 24 patients in a scheduled meeting, found no safety concerns, and recommended continuation of the trial to completion without changes. REFRESH (REduction in FREe Hemoglobin) I is a company-sponsored 40-patient, multi-center, randomized, controlled safety and feasibility study using CytoSorb® intra-operatively during elective, non-emergent complex cardiac surgery where cardiopulmonary bypass is expected to last longer than 3 hours.
05/26/16 07:47 AMTarget Check and Stock Performance Recap Cytosorbents Corporation (NASDAQ:CTSO) - Wall Street Hints and News - Target Check and Stock Performance Recap Cytosorbents Corporation (NASDAQ:CTSO)Wall Street Hints and NewsIn recent session activity, Cytosorbents Corporation (NASDAQ:CTSO) shares have traded -1.68%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has been ...and more »
03/14/16 01:48 PMAnalysts Speculate on Two Biotech Stocks: Anavex Life Sciences Corp. (AVXL) and Cytosorbents Corp (CTSO) - Smarter Analyst - Smarter AnalystAnalysts Speculate on Two Biotech Stocks: Anavex Life Sciences Corp. (AVXL) and Cytosorbents Corp (CTSO)Smarter AnalystOptimistic views on Alzheimer remedy in its making by Anavex Life Sciences Corp (NYSE:AVXL) and improved earnings report by Cytosorbents Corp (NASDAQ:CTSO) caused analysts to reiterate Buy ratings on both companies. Let's take a closer look:.and more »
03/14/16 10:45 AMCytoSorbents Corp. :CTSO-US: Earnings Analysis: Q4, 2015 By the Numbers -
02/26/16 01:22 PMCytosorbents Gains 10% Following Encouraging Top Line Results - Shares of Cytosorbents Corp (NASDAQ: CTSO) gained more than 10 percent on Friday after the company presented data from its first CytoSorb investigator-initiated septic shock study at an industry conference in Germany. According to the company's press release, "All patients had refractory septic shock despite high doses of vasopressors, respiratory failure requiring artificial ventilation or extracorporeal membrane oxygenation (ECMO), anuric (no urine production) ...Full story available on Benzinga.com
02/26/16 11:19 AMData Presented on First CytoSorb® Investigator-Initiated Septic Shock Study - PR Newswire (press release) - Data Presented on First CytoSorb® Investigator-Initiated Septic Shock StudyPR Newswire (press release)MONMOUTH JUNCTION, N.J., Feb. 26, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac ...and more »
02/26/16 11:19 AMIs Cytosorbents Corp a Buy? The Stock Rises Again - Business Standard Tribune - Is Cytosorbents Corp a Buy? The Stock Rises AgainBusiness Standard TribuneThe stock of Cytosorbents Corp (NASDAQ:CTSO) is a huge mover today! The stock increased 6.41% or $0.28 on February 25, hitting $4.65. About 64,104 shares traded hands. Cytosorbents Corp (NASDAQ:CTSO) has declined 34.19% since July 21, 2015 ...
02/14/16 01:00 PMCytosorbents Corporation (NASDAQ:CTSO) Sellers Increased By 12.45% Their Shorts - fdanewsalert.com - Cytosorbents Corporation (NASDAQ:CTSO) Sellers Increased By 12.45% Their Shortsfdanewsalert.comThe stock of Cytosorbents Corporation (NASDAQ:CTSO) registered an increase of 12.45% in short interest. CTSO's total short interest was 554,700 shares in February as published by FINRA. Its up 12.45% from 493,300 shares, reported previously.What Will Happen to Cytosorbents Corp Next? The Stock Just Increased A LotSonoran Weekly Reviewall 2 news articles »
02/09/16 01:38 PMCytosorbents Corporation (NASDAQ:CTSO) Shorts Decreased by 0.6% After Short Covering - fdanewsalert.com - Cytosorbents Corporation (NASDAQ:CTSO) Shorts Decreased by 0.6% After Short Coveringfdanewsalert.comThe stock of Cytosorbents Corporation (NASDAQ:CTSO) registered a decrease of 0.6% in short interest. CTSO's total short interest was 493,300 shares in February as published by FINRA. Its down 0.6% from 496,300 shares, reported previously. With 130,800 ...
02/04/16 01:07 PMCytoSorbents to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference - PR Newswire (press release) - CytoSorbents to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare ConferencePR Newswire (press release)MONMOUTH JUNCTION, N.J., Feb. 4, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery ...and more »
02/02/16 12:48 PMCytoSorbents Corporation Gets $325000 Non-Dilutive Funding From New Jersey Tax Program (NASDAQ:CTSO) - WallStreet.org - CytoSorbents Corporation Gets $325000 Non-Dilutive Funding From New Jersey Tax Program (NASDAQ:CTSO)WallStreet.orgCytoSorbents Corporation (NASDAQ:CTSO) shares were higher over 3% on Monday after announcing the receipt of $324,606, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer ...Recent Broker Updates On CytoSorbents Co. (CTSO)Risers & FallersCytoSorbents Receives $325000 in Non-Dilutive FundingInvesting News Network (press release) (registration) (blog)CytoSorbents Receives $325000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate ...PR Newswire (press release)all 7 news articles »
02/01/16 12:35 PMCytosorbents Corporation (NASDAQ:CTSO): Stock in the spotlight - Stocks Daily - Cytosorbents Corporation (NASDAQ:CTSO): Stock in the spotlightStocks DailyCytosorbents Corporation (NASDAQ:CTSO) has successfully managed to attain positive rating on its stock. Zacks planned a poll of sell-side experts after which the firm assigned 1.2 rating on company's stock. This consensus rating, which is placed on a ...Company Shares of Cytosorbents Corporation (NASDAQ:CTSO) Drops by -6.11%Bull ReportGainers on Major News: Sony Corp (ADR) (NYSE:SNE), Yahoo! Inc. (NASDAQ:YHOO), Alphabet Inc (NASDAQ ...Benchmark Monitorall 3 news articles »
01/31/16 07:03 PMCompany Shares of Cytosorbents Corporation (NASDAQ:CTSO) Drops by -6.11% - Bull Report - Company Shares of Cytosorbents Corporation (NASDAQ:CTSO) Drops by -6.11%Bull ReportCytosorbents Corporation (NASDAQ:CTSO) has lost 6.11% during the past week and dropped 31.06% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 7.73%. Cytosorbents Corporation ...
01/30/16 12:18 PMCytoSorbents to Present at the 18th Annual BIO CEO & Investor Conference - PR Newswire (press release) - CytoSorbents to Present at the 18th Annual BIO CEO & Investor ConferencePR Newswire (press release)MONMOUTH JUNCTION, N.J., Jan. 28, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac ...and more »
01/28/16 12:32 PMCytoSorbents to Present at the 18th Annual BIO CEO & Investor Conference - CNNMoney - CytoSorbents to Present at the 18th Annual BIO CEO & Investor ConferenceCNNMoney28, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, ...
01/28/16 12:32 PMCytosorbents Corporation (NASDAQ:CTSO): Quarterly Earnings Update - Investor Newswire - Cytosorbents Corporation (NASDAQ:CTSO): Quarterly Earnings UpdateInvestor NewswireAs per the brokerage research firms surveyed by Zacks Research, Cytosorbents Corporation (NASDAQ:CTSO) is expected to post earnings per share of $-0.08 for last fiscal quarter. The company can announce the results on or around 2016-03-29. Since the ...and more »
01/25/16 06:50 PMCompany Shares of Cytosorbents Corporation (NASDAQ:CTSO) Drops by -5.1% - The Daily Rover - Company Shares of Cytosorbents Corporation (NASDAQ:CTSO) Drops by -5.1%The Daily RoverCytosorbents Corporation (NASDAQ:CTSO) has lost 5.1% during the past week and dropped 35.59% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 6.43%. Cytosorbents Corporation ...
01/22/16 06:43 PMCytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical Affairs - CNNMoney - CytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical AffairsCNNMoney21, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its European Union approved CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients ...and more »
01/21/16 11:47 AMCytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical Affairs - PR Newswire (press release) - CytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical AffairsPR Newswire (press release)21, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its European Union approved CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients ...and more »
01/20/16 06:45 PMCytosorbents Corporation (NASDAQ:CTSO) - Stock Sentiment And ABR Update - Investor Newswire - Cytosorbents Corporation (NASDAQ:CTSO) - Stock Sentiment And ABR UpdateInvestor NewswireZacks Research has given an average broker rating of 1.2 to Cytosorbents Corporation (NASDAQ:CTSO)'s shares. Zacks assigns a simplified score in between one and five against the complex analysts' ratings. A score towards 1-2 typically means a ...and more »
About Cytosorbents Corp

Cytosorbents Corp logoCytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: CTSO
  • CUSIP:
Key Metrics:
  • Previous Close: $4.55
  • 50 Day Moving Average: $4.36
  • 200 Day Moving Average: $4.55
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $115.62M
  • Current Quarter EPS Consensus Estimate: $-0.35 EPS
Additional Links:
Cytosorbents Corp (OTCMKTS:CTSO) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha